Leerink Partners Adjusts Price Target on DexCom to $87 From $94
Leerink Partners has lowered its price target for DexCom, Inc. from $94 to $87.
Stocks · News reference
Dexcom Announces Canadian Launch of G7 15-Day Continuous Glucose Monitoring System
DexCom, Inc. announced that its G7 15-day continuous glucose monitoring (CGM) system will be available in Canada starting in November 2026 for adults aged 18 and older.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Dexcom's CONNECT trial results, published in The New England Journal of Medicine, demonstrate that its G7 continuous glucose monitoring system achieves a 1.6% A1C reduction in non-insulin-treated Type 2 diabetes patients, with 97% adherence at 26 weeks. The findings support broader CGM adoption and could expand market opportunities, though success depends on physician adoption and insurance coverage. The global CGM market is projected to grow from $13.4 billion in 2025 to $41.4 billion by 2033.